FDA Slacking On Post-Approval Follow-Up: Report

Law360, New York (July 11, 2006, 12:00 AM EDT) -- As concern over drug safety regulation and procedures continues to mount, a newly-released report by the inspector general of the U.S. Health and Human Services Department points the finger of blame at the U.S. Food and Drug Administration.

The report accuses the agency of failing to track the status of many post-approval safety studies.

All new drugs are required by the FDA to undergo clinical testing to demonstrate their safety prior to approval for sale in the U.S., but these mandatory pre-market trials involve relatively small...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.